Rapidly progressive glomerulonephritis classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Rapidly progressive glomerulonephritis is classified on the basis of cause of [[Glomerulus|glomerular]] injury.The [[Immunofluorescence|immunoflourescent microspcopic]] findings are used in determining the cause of glomerular injury.


==Classification==
==Classification==
Line 11: Line 12:
===Type I===
===Type I===
* Type I RPGN is characterized by the presence of [[autoantibodies]] directed against the [[glomerular basement membrane]] (GBM)<ref name="pmid8909258">{{cite journal| author=Heeringa P, Brouwer E, Klok PA, Huitema MG, van den Born J, Weening JJ et al.| title=Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat. | journal=Am J Pathol | year= 1996 | volume= 149 | issue= 5 | pages= 1695-706 | pmid=8909258 | doi= | pmc=1865281 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8909258  }} </ref>.  
* Type I RPGN is characterized by the presence of [[autoantibodies]] directed against the [[glomerular basement membrane]] (GBM)<ref name="pmid8909258">{{cite journal| author=Heeringa P, Brouwer E, Klok PA, Huitema MG, van den Born J, Weening JJ et al.| title=Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat. | journal=Am J Pathol | year= 1996 | volume= 149 | issue= 5 | pages= 1695-706 | pmid=8909258 | doi= | pmc=1865281 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8909258  }} </ref>.  
* Type I also known as anti-[[GBM]] glomerulonephritis.  
* Type I also known as anti-[[GBM]] [[Glomerular disease|glomerulonephritis.]]
* The antibodies formed are known as anticollagen antibodies and react against type IV [[collagen]] of [[GBM]].<ref name="robbins">{{cite book |author=Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. |title=Robbins and Cotran pathologic basis of disease |publisher=Elsevier Saunders |location=St. Louis, MO |year=2005 |pages=pp976-8 |isbn=0-7216-0187-1 |oclc= |doi=}}</ref>
* The antibodies formed are known as anticollagen antibodies and react against type IV [[collagen]] of [[GBM]].<ref name="robbins">{{cite book |author=Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. |title=Robbins and Cotran pathologic basis of disease |publisher=Elsevier Saunders |location=St. Louis, MO |year=2005 |pages=pp976-8 |isbn=0-7216-0187-1 |oclc= |doi=}}</ref>
* The antibodies can be produced by a stimulus such as viral [[Upper respiratory tract infection|URTI]] that exposes alveolar collagen membrane or it can be idiopathic.
* The antibodies can be produced by a stimulus such as viral [[Upper respiratory tract infection|URTI]] that exposes [[Alveolus|alveolar]] collagen membrane or it can be idiopathic.
* The antibodies formed can act against alveolar membrane and lungs get involved in some cases such as in [[goodpasture syndrome]].
* The antibodies formed can act against alveolar membrane and lungs get involved in some cases such as in [[goodpasture syndrome]].


Line 24: Line 25:
* [[Connective tissue disease|Connective tissue disorders]]
* [[Connective tissue disease|Connective tissue disorders]]
* [[Lupus nephritis]]
* [[Lupus nephritis]]
* [[Henoch-Schönlein purpura|Henoch-Schönlein purpural]])
* [[Henoch-Schönlein purpura|Henoch-Schönlein purpura]]
* [[IgA nephropathy|Immunoglobulin A nephropathy]]
* [[IgA nephropathy|Immunoglobulin A nephropathy]]
* Mixed [[cryoglobulinemia]]
* Mixed [[cryoglobulinemia]]
Line 33: Line 34:
* There are no anti [[GBM]] antibodies or no [[Immune complex|immune complexes]] involved.
* There are no anti [[GBM]] antibodies or no [[Immune complex|immune complexes]] involved.
* It is further classified into 2 types:
* It is further classified into 2 types:
** Immunogenic - ANCA positive
** Immunogenic - [[Anti-neutrophil cytoplasmic antibody|ANCA]] positive
** Non immunogenic- ANCA negative/ Idiopathic
** Non immunogenic- ANCA negative/ Idiopathic
* ANCAs cause the release of lytic enzymes from neutrophils that damage the GBM.
* ANCAs cause the release of lytic enzymes from [[Neutrophil|neutrophils]] that damage the GBM.
* Systemic [[vasculitis]] is present in most of the cases but some occur without systemic involvement and only renal findings maybe present.
* Systemic [[vasculitis]] is present in most of the cases but some occur without systemic involvement and only renal findings maybe present.
* Examples include   
* Examples include   
Line 42: Line 43:
** Renal-limited necrotizing crescentic glomerulonephritis (NCGN)
** Renal-limited necrotizing crescentic glomerulonephritis (NCGN)
** [[Langerhans cell histiocytosis|Eosinophilic granulomatosis]] with polyangiitis (EGPA; Churg-Strauss syndrome)
** [[Langerhans cell histiocytosis|Eosinophilic granulomatosis]] with polyangiitis (EGPA; Churg-Strauss syndrome)
** Drugs- hydralazine, allopurinol and rifampin.
** Drugs- [[hydralazine]], [[allopurinol]] and [[rifampin]].


==References==
==References==

Revision as of 16:13, 23 July 2018

Rapidly progressive glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rapidly progressive glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray Findings

CT-scan Findings

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Rapidly progressive glomerulonephritis classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rapidly progressive glomerulonephritis classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rapidly progressive glomerulonephritis classification

CDC on Rapidly progressive glomerulonephritis classification

Rapidly progressive glomerulonephritis classification in the news

Blogs on Rapidly progressive glomerulonephritis classification

Directions to Hospitals Treating Rapidly progressive glomerulonephritis

Risk calculators and risk factors for Rapidly progressive glomerulonephritis classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Rapidly progressive glomerulonephritis is classified on the basis of cause of glomerular injury.The immunoflourescent microspcopic findings are used in determining the cause of glomerular injury.

Classification

RPGN is classified on the basis of the cause of glomerular injury and the findings from light and immunofluorescence microscopy.[1][2].

Type I

Type II

Type III

References

  1. Couser WG (1988). "Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy". Am J Kidney Dis. 11 (6): 449–64. PMID 3287904.
  2. Couser WG (1998). "Pathogenesis of glomerular damage in glomerulonephritis". Nephrol Dial Transplant. 13 Suppl 1: 10–5. PMID 9507491.
  3. Heeringa P, Brouwer E, Klok PA, Huitema MG, van den Born J, Weening JJ; et al. (1996). "Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat". Am J Pathol. 149 (5): 1695–706. PMC 1865281. PMID 8909258.
  4. 4.0 4.1 Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease. St. Louis, MO: Elsevier Saunders. pp. pp976–8. ISBN 0-7216-0187-1.